LAG3 Expression in Triple Negative Breast Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
AgeNot listed
SponsorSamsung Medical Center
About this trial
This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.
Eligibility criteria
Qualifiers
Planned neoadjuvant chemotherapy
Triple negative breast cancer
Disqualifiers
HER2-positive breast cancer
Hormone receptor positive breast cancer
Trial design
Treatments tested in this trial
- LAG-3 expression / immune checkpoint protein expression
Treatment groups
128 Participants
are divided into 1 treatment groupLocations
1Ji-Yeon Kim06351, Seoul South Korea
Sponsors and collaborators
Samsung Medical Center
Lead sponsor
Source ClinicalTrials.gov